Abstract 952: MORAb-202, a folate receptor-alpha (FRA)-targeting antibody-eribulin drug conjugate (ADC), exhibits durable antitumor activity and payload-mediated bystander effects on the tumor microenvironment in triple-negative breast cancerMORAb-202 is an antibody drug conjugate (ADC) consisting of...
Moore, K. N. et al. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.Gynecol. Oncol.151, 46...
关键词:FolateReceptoralpha(FR-alpha)蛋白 公司同类产品 (E/Z)-BSPOTPE 官网链接:https://www.medchemexpress.cn/e-z-bspotpe.html(E/Z)-BSPOTPE 是 BSPOTPE (HY-W856375) 的构型混合物。BSPOT更多详细 荧光素O-甲基丙烯酸酯 官网链接:https://www.medchemexpress.cn/fluorescein-o-methacrylate.htmlFluo...
Folate receptor alpha (FRα), encoded by the FOLR1 gene, is an attractive therapeutically target due to its prevalent and high expression in EOC cells. Recent basic and translational studies have explored several modalities, such as antibody-drug conjugate (ADC), monoclonal antibodies, small ...
Antibodies specific to folate receptor alpha (a.k.a. folate receptor 1 or FOLR1) and uses thereof for therapeutic and diagnostic purposes. Also provided herein are chimeric antigen receptors (CARs) comprising an extracellular antigen-binding fragment that binds FOLR1 and immune cells expressing such...
Targeted protein degradation has emerged as a novel therapeutic modality to treat human diseases by utilizing the cell’s own disposal systems to remove protein target. Significant clinical benefits have been observed for degrading many intracellular pro
The efficacy of HAdV-C5-based OV is hampered by a lack of tumour selectivity, where the primary receptor, hCAR, is commonly downregulated during malignant transformation. Conversely, folate receptor alpha (FRα) is highly expressed on ovarian cancer cells, providing a compelling target for tumour...
Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes Article Open access 19 November 2022 Exploiting the folate receptor α in oncology Article 09 March 2020 ADC: a deadly killer of platinum resistant ovarian cancer Article Ope...
Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers. Mol. Cancer Ther. 2023, 22, 155–167. [Google Scholar] [CrossRef] Oaknin, A.; Fariñas-Madrid, L.; García-Duran, C.; Martin, L.P.; O’Malley, D...
Elevated folate receptor alpha (FRα) expression is characteristic of epithelial ovarian cancer (EOC), thus establishing this receptor as a candidate target for the development of novel therapeutics to treat this disease. Mirvetuximab soravtansine (IMGN853) is an antibody-drug conjugate (ADC) th...